BiotechTube

Placebo + ibandronate [Bonviva/Boniva]

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Post-Menopausal Osteopenia

Conditions

Post-Menopausal Osteopenia

Trial Timeline

Dec 1, 2005 → Dec 1, 2007

NCT ID
NCT00129623

About Placebo + ibandronate [Bonviva/Boniva]

Placebo + ibandronate [Bonviva/Boniva] is a approved stage product being developed by Roche for Post-Menopausal Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00129623. Target conditions include Post-Menopausal Osteopenia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00493623Phase 3Completed
NCT00129623ApprovedCompleted

Competing Products

19 competing products in Post-Menopausal Osteopenia

See all competitors
ProductCompanyStageHype Score
raloxifene + PlaceboEli LillyApproved
85
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
Teriparatide + Zoledronic AcidEli LillyApproved
85
teriparatideEli LillyPhase 3
77
Raloxifene + Raloxifene + PlaceboEli LillyApproved
85
TeriparatideEli LillyApproved
85
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
MK0429MerckPhase 2
52
PTH134 + Placebo + ForsteoNovartisPhase 1
33
Placebo + Zoledronic acidNovartisPhase 3
77
zoledronic acid + Any oral bisphosphonates marketed in CanadaNovartisPre-clinical
23
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
85
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
85
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
85
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
77
IbandronateRochePhase 3
77
romosozumab HCP administration with PFSAmgenPhase 3
76
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo AlendronateAmgenPhase 2
51
BAY3427080 + Placebo (for BAY3427080)BayerPhase 1/2
38

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85